Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v9-FR | Version v2-FR | |
---|---|---|
Language | French | French |
Date Updated | 2021-08-19 | 2021-02-05 |
Drug Identification Number | 02406411 | 02406411 |
Brand name | HALOPERIDOL INJECTION, USP | HALOPERIDOL INJECTION, USP |
Common or Proper name | Haloperidol Injection, USP 5 mg/mL 1 mL | Haloperidol Injection, USP 5 mg/mL 1 mL |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | HALOPERIDOL | HALOPERIDOL |
Strength(s) | 5MG | 5MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | 1 mL | 1 mL |
ATC code | N05AD | N05AD |
ATC description | ANTIPSYCHOTICS | ANTIPSYCHOTICS |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-06-01 | 2021-02-02 |
Actual start date | 2021-06-01 | 2021-02-02 |
Estimated end date | 2021-08-20 | Unknown |
Actual end date | 2019-08-20 | |
Shortage status | Avoided shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | [5/27/2021] Fresenius Kabi Canada Ltd. regrets to advise that due to a delay in production we will be encountering a supply interruption on our Haloperidol Injection, USP 5 mg/mL MD Vial 1 mL, effective June 1st, 2021 until August 23rd, 2021. | Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints our Haloperidol Injection, USP 5 mg/mL MD Vial 1 mL will be placed on allocation. Contract customers will be allocated 100% of their historical average monthly volumes, effective February 2, 2021. |
Health Canada comments |